£2.5M
The biotechnology funding pairs strategic capital with a collaborative agreement to explore oncology opportunities.
"This strategic investment is an important endorsement of AMPLY's platform and our approach to oncology. We're building a company designed for partnering – generating high-quality, data-driven programmes and taking them to clear inflection points. We're delighted to welcome Keeps Biomed as a strategic investor, and to bring Oliver on board as CSO to help sharpen our oncology execution and partnering readiness."